Overview

Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder

Status:
Not yet recruiting

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

In The Netherlands, each year, about 15 thousand people come into treatment because of problems with cocaine use. There is no approved medication for treatment of cocaine addiction and the psychosocial treatment patients receive is not successful for everyone; many return to treatment several times. There is evidence that agonist ("replacement") medications are effective in treating addiction: methadone for heroin addiction; nicotine replacement for smokers. Dexamphetamine is a stimulant medication registered for treatment of ADHD. It may also be effective as agonist treatment for people with cocaine addiction. It will be investigated whether sustained-release dexamphetamine in people with cocaine addiction, participating in routine methadone maintenance treatment for their comorbid opioid use disorder, (1) reduces cocaine use and (2) improves their health and quality of life.

Phase:

Phase 2

Details

Lead Sponsor:

Parnassia Addiction Research Centre

Collaborators:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Columbia University
Het Zwarte Gat
Leiden University Medical Center
Radboud University Medical Center
The Netherlands Cancer Institute

Treatments:

Dextroamphetamine